-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
On June 2nd, Boji Biomedical Technology (Hangzhou) Co.
BJ-005 is a recombinant dual-function fusion of a humanized anti-programmed death ligand 1 (PD-L1) IgG1 monoclonal antibody and a part of the extracellular domain of human transforming growth factor β (TGF-β) receptor II The fusion protein can simultaneously target PD-L1 and TGF-β, inhibit tumor growth by targeting immune checkpoints and regulating tumor cell growth cytokine pathways, and is used to treat cancer patients
Note: The original text has been deleted